586 related articles for article (PubMed ID: 33452559)
21. Nab-Paclitaxel and Gemcitabine as First-line Treatment of Advanced or Metastatic Cholangiocarcinoma: A Phase 2 Clinical Trial.
Sahai V; Catalano PJ; Zalupski MM; Lubner SJ; Menge MR; Nimeiri HS; Munshi HG; Benson AB; O'Dwyer PJ
JAMA Oncol; 2018 Dec; 4(12):1707-1712. PubMed ID: 30178032
[TBL] [Abstract][Full Text] [Related]
22. Open-label, Phase I Study of Nivolumab Combined with
Wainberg ZA; Hochster HS; Kim EJ; George B; Kaylan A; Chiorean EG; Waterhouse DM; Guiterrez M; Parikh A; Jain R; Carrizosa DR; Soliman HH; Lila T; Reiss DJ; Pierce DW; Bhore R; Banerjee S; Lyons L; Louis CU; Ong TJ; O'Dwyer PJ
Clin Cancer Res; 2020 Sep; 26(18):4814-4822. PubMed ID: 32554514
[TBL] [Abstract][Full Text] [Related]
23. Quality of life and outcome of patients with metastatic pancreatic cancer receiving first-line chemotherapy with nab-paclitaxel and gemcitabine: Real-life results from the prospective QOLIXANE trial of the Platform for Outcome, Quality of Life and Translational Research on Pancreatic Cancer registry.
Al-Batran SE; Hofheinz RD; Reichart A; Pauligk C; Schönherr C; Schlag R; Siegler G; Dörfel S; Koenigsmann M; Zahn MO; Schubert J; Aldaoud A; Höffkes HG; Schulz H; Hahn L; Uhlig J; Blau W; Stauch M; Weniger J; Wolf M; Jacobasch L; Bildat S; Wehmeyer J; Homann N; Trojan J; Waidmann O; Fietz T; Feustel HP; Groschek M; Wierecky J; Waibel K; Mahlmann S; Schwindel U; Peters U; Schuch G; Pink D; Eschenburg H; Wörns MA; Harich HD; von Weikersthal LF; Däßler KU; Behringer DM; Messmann H; Kretzschmar A; Gallmeier E; Forstbauer H; Kunzmann V; Papke J; Büchner-Steudel P; Vehling-Kaiser U; Springfeld C; Vogel A; Ettrich TJ; Schaaf M; Hausen GZ; Götze TO;
Int J Cancer; 2021 Mar; 148(6):1478-1488. PubMed ID: 33038277
[TBL] [Abstract][Full Text] [Related]
24. Phase Ib Study of Wnt Inhibitor Ipafricept with Gemcitabine and nab-paclitaxel in Patients with Previously Untreated Stage IV Pancreatic Cancer.
Dotan E; Cardin DB; Lenz HJ; Messersmith W; O'Neil B; Cohen SJ; Denlinger CS; Shahda S; Astsaturov I; Kapoun AM; Brachmann RK; Uttamsingh S; Stagg RJ; Weekes C
Clin Cancer Res; 2020 Oct; 26(20):5348-5357. PubMed ID: 32694153
[TBL] [Abstract][Full Text] [Related]
25. Efficacy and safety of weekly nab-paclitaxel plus gemcitabine in Chinese patients with metastatic adenocarcinoma of the pancreas: a phase II study.
Xu R; Yu X; Hao J; Wang L; Pan H; Han G; Xu J; Zhang Y; Yang S; Chen J; Ying J; Dai G; Li M; Begic D; Lu B; Shen L
BMC Cancer; 2017 Dec; 17(1):885. PubMed ID: 29273007
[TBL] [Abstract][Full Text] [Related]
26. Clinical Outcomes and Safety of Patients Treated with NAb-Paclitaxel Plus Gemcitabine in Metastatic Pancreatic Cancer: The NAPA Study.
Catalano M; Roviello G; Conca R; D'Angelo A; Palmieri VE; Panella B; Petrioli R; Ianza A; Nobili S; Mini E; Ramello M
Curr Cancer Drug Targets; 2020; 20(11):887-895. PubMed ID: 32957885
[TBL] [Abstract][Full Text] [Related]
27. A randomised phase 2 trial of nab-paclitaxel plus gemcitabine with or without capecitabine and cisplatin in locally advanced or borderline resectable pancreatic adenocarcinoma.
Reni M; Zanon S; Balzano G; Passoni P; Pircher C; Chiaravalli M; Fugazza C; Ceraulo D; Nicoletti R; Arcidiacono PG; Macchini M; Peretti U; Castoldi R; Doglioni C; Falconi M; Partelli S; Gianni L
Eur J Cancer; 2018 Oct; 102():95-102. PubMed ID: 30149366
[TBL] [Abstract][Full Text] [Related]
28. Real world evidence on gemcitabine and nab-paclitaxel combination chemotherapy in advanced pancreatic cancer.
Blomstrand H; Scheibling U; Bratthäll C; Green H; Elander NO
BMC Cancer; 2019 Jan; 19(1):40. PubMed ID: 30621618
[TBL] [Abstract][Full Text] [Related]
29. Safety and efficacy of Nab-paclitaxel plus gemcitabine in patients with advanced pancreatic cancer suffering from cholestatic hyperbilirubinaemia-A retrospective analysis.
Pelzer U; Wislocka L; Jühling A; Striefler J; Klein F; Roemmler-Zehrer J; Sinn M; Denecke T; Bahra M; Riess H
Eur J Cancer; 2018 Sep; 100():85-93. PubMed ID: 30014884
[TBL] [Abstract][Full Text] [Related]
30. Phase I/II Trial to Evaluate the Efficacy and Safety of Nanoparticle Albumin-Bound Paclitaxel in Combination With Gemcitabine in Patients With Pancreatic Cancer and an ECOG Performance Status of 2.
Macarulla T; Pazo-Cid R; Guillén-Ponce C; López R; Vera R; Reboredo M; Muñoz Martin A; Rivera F; Díaz Beveridge R; La Casta A; Martín Valadés J; Martínez-Galán J; Ales I; Sastre J; Perea S; Hidalgo M
J Clin Oncol; 2019 Jan; 37(3):230-238. PubMed ID: 30523758
[TBL] [Abstract][Full Text] [Related]
31. Efficacy of Nab-Paclitaxel Plus Gemcitabine and Prognostic Value of Peripheral Neuropathy in Patients with Metastatic Pancreatic Cancer.
You MS; Ryu JK; Choi YH; Choi JH; Huh G; Paik WH; Lee SH; Kim YT
Gut Liver; 2018 Nov; 12(6):728-735. PubMed ID: 30400731
[TBL] [Abstract][Full Text] [Related]
32. Impact on health-related quality of life deterioration-free survival of a first-line therapy combining nab-paclitaxel plus either gemcitabine or simplified leucovorin and fluorouracil for patients with metastatic pancreatic cancer: Results of the randomized phase II AFUGEM GERCOR clinical trial.
Charton E; Bachet JB; Hammel P; Desramé J; Chibaudel B; Cohen R; Debourdeau P; Dauba J; Lecomte T; Seitz JF; Tournigand C; Aparicio T; Guerin-Meyer V; Taieb J; Volet J; Louvet C; Anota A; Bonnetain F
Cancer Med; 2019 Sep; 8(11):5079-5088. PubMed ID: 31314957
[TBL] [Abstract][Full Text] [Related]
33. Development of peripheral neuropathy and its association with survival during treatment with nab-paclitaxel plus gemcitabine for patients with metastatic adenocarcinoma of the pancreas: A subset analysis from a randomised phase III trial (MPACT).
Goldstein D; Von Hoff DD; Moore M; Greeno E; Tortora G; Ramanathan RK; Macarulla T; Liu H; Pilot R; Ferrara S; Lu B
Eur J Cancer; 2016 Jan; 52():85-91. PubMed ID: 26655559
[TBL] [Abstract][Full Text] [Related]
34. A Randomized, Double-Blinded, Phase II Trial of Gemcitabine and Nab-Paclitaxel Plus Apatorsen or Placebo in Patients with Metastatic Pancreatic Cancer: The RAINIER Trial.
Ko AH; Murphy PB; Peyton JD; Shipley DL; Al-Hazzouri A; Rodriguez FA; Womack MS; Xiong HQ; Waterhouse DM; Tempero MA; Guo S; Lane CM; Earwood C; DeBusk LM; Bendell JC
Oncologist; 2017 Dec; 22(12):1427-e129. PubMed ID: 28935773
[TBL] [Abstract][Full Text] [Related]
35. Nab-paclitaxel and gemcitabine or FOLFIRINOX as first-line treatment in patients with unresectable adenocarcinoma of the pancreas: does sequence matter?
Vogl UM; Andalibi H; Klaus A; Vormittag L; Schima W; Heinrich B; Kafka A; Winkler T; Öhler L
BMC Cancer; 2019 Jan; 19(1):28. PubMed ID: 30621630
[TBL] [Abstract][Full Text] [Related]
36. Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective multicentre cohort.
Portal A; Pernot S; Tougeron D; Arbaud C; Bidault AT; de la Fouchardière C; Hammel P; Lecomte T; Dréanic J; Coriat R; Bachet JB; Dubreuil O; Marthey L; Dahan L; Tchoundjeu B; Locher C; Lepère C; Bonnetain F; Taieb J
Br J Cancer; 2015 Sep; 113(7):989-95. PubMed ID: 26372701
[TBL] [Abstract][Full Text] [Related]
37. nab-Paclitaxel plus gemcitabine in metastatic pancreatic adenocarcinoma: Australian subset analyses of the phase III MPACT trial.
Young R; Mainwaring P; Clingan P; Parnis FX; Asghari G; Beale P; Aly A; Botteman M; Romano A; Ferrara S; Margunato-Debay S; Harris M
Asia Pac J Clin Oncol; 2018 Oct; 14(5):e325-e331. PubMed ID: 29932294
[TBL] [Abstract][Full Text] [Related]
38. Positron emission tomography response evaluation from a randomized phase III trial of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone for patients with metastatic adenocarcinoma of the pancreas.
Ramanathan RK; Goldstein D; Korn RL; Arena F; Moore M; Siena S; Teixeira L; Tabernero J; Van Laethem JL; Liu H; McGovern D; Lu B; Von Hoff DD
Ann Oncol; 2016 Apr; 27(4):648-53. PubMed ID: 26802153
[TBL] [Abstract][Full Text] [Related]
39. Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): study protocol for a randomized controlled trial.
Yardley DA; Brufsky A; Coleman RE; Conte PF; Cortes J; Glück S; Nabholtz JM; O'Shaughnessy J; Beck RM; Ko A; Renschler MF; Barton D; Harbeck N
Trials; 2015 Dec; 16():575. PubMed ID: 26673577
[TBL] [Abstract][Full Text] [Related]
40. Efficacy and treatment-related adverse events of gemcitabine plus nab-paclitaxel for treatment of metastatic pancreatic cancer "in a Korean" population: A single-center cohort study.
Cho IR; Kang H; Jo JH; Lee HS; Chung MJ; Park JY; Park SW; Song SY; Chung JB; An C; Park MS; Jung SY; Bang S
Semin Oncol; 2017 Dec; 44(6):420-427. PubMed ID: 29935903
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
